Amgen looks for Five Prime payback
A key pivotal study of bemarituzumab will read out shortly.
Yet more conjugates enter the clinic
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Private US biotechs head for human trials
Halda, Accent and Vividion take more projects into phase 1.
Jabez heads for the clinic
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
